Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
The purpose of this study is to assess whether changing antiepileptic medication can reduce side effects and improve the quality of life in patients with epileptic seizures that are well controlled with antiepileptic drugs.
Background. The aim of the treatment with antiepileptic drugs (AEDs) is to achieve seizure freedom without causing side effects. Assessment of side effects is difficult. They may start insidiously, the patient may not associate certain complaints with the use of AEDs, or the treating physician does not take enough time to discuss this topic during the limited time of a visit in the outpatient department. We know from clinical trials that side effects occur in a substantial group of patients. We do not know whether we deal with this possible complication in an adequate way in clinical practice.
Study objective. To study whether adjustment of medication will reduce the occurrence of side effects and improve quality of life.
Study design. A randomised clinical trial comparing adjustment of treatment in case of relevant side effects to continuing treatment unchanged. Relevant side effects are defined as at least one moderate or serious problem scored on a questionnaire to assess complaints in people with epilepsy.
Patients who do not report relevant side effects will be followed for 13 months (arm A) in which two visits are scheduled, after 7 and 13 months respectively.
The patients who do report relevant side effects will be randomised to either discussion of the questionnaire results and adjustment of treatment if appropriate (arm B) or to ignore the results of the questionnaire and continue treatment unchanged (arm C). Investigations will be repeated in both groups after 7 and 13 months after the initial visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| All registered antiepileptic drugs | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Complaints (questionnaire) at 7 and 13 months |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life (Qolie-10) at 7 and 13 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cees A van Donselaar, MD PhD | UMC Utrecht | Study Director |
| Sabine G Uijl, MSc | UMC Utrecht | Principal Investigator |
| Albert P Aldenkamp, PhD | AZM Maastricht | Principal Investigator |
| Cuno SP Uiterwaal, PhD | UMC Utrecht | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AZM | Maastricht | Limburg | 6202 AZ | Netherlands | ||
| Catharina Hospital |
Not provided
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Eindhoven |
| North Brabant |
| 5623 EJ |
| Netherlands |
| Hospital Gooi-Noord | Blaricum | North Holland | 1250 CA | Netherlands |
| MCRZ | Rotterdam | South Holland | 3007 AC | Netherlands |
| MC Haaglanden | The Hague | South Holland | 2512 VA | Netherlands |
| Oosterschelde Hospital | Goes | Zeeland | 4460 BB | Netherlands |